New treatments for headache

Neurol Sci. 2017 May;38(Suppl 1):145-156. doi: 10.1007/s10072-017-2910-0.

Abstract

Headache disorders are common worldwide and often disabling. Until recently, treatments were borrowed from other branches of neurology and medicine. Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) ligand and receptor, small molecule CGRP receptor antagonist gepants, serotonin1F agonists, new devices to deliver currently available drugs, and neuromodulation devices have recently been in the forefront of headache treatments that are rather specific for various headache disorders. These novel therapies are changing the field of headache medicine. Herein, we update the latest data available for these therapies.

Keywords: Calcitonin gene-related peptide (CGRP); Headache treatment; Magnetic stimulation; Monoclonal antibodies; Neuromodulation; Neurostimulation.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Calcitonin Gene-Related Peptide / antagonists & inhibitors*
  • Calcitonin Gene-Related Peptide / metabolism
  • Headache Disorders / diagnosis*
  • Headache Disorders / drug therapy*
  • Headache Disorders / metabolism
  • Humans
  • Neurotransmitter Agents / administration & dosage
  • Piperidines / administration & dosage
  • Pyridines / administration & dosage
  • Serotonin Receptor Agonists / administration & dosage
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • CALCA protein, human
  • Neurotransmitter Agents
  • Piperidines
  • Pyridines
  • Serotonin Receptor Agonists
  • rimegepant sulfate
  • Calcitonin Gene-Related Peptide